Serodopa Therapeutics Inc.

Gainesville, FL

UEI
V53SJEC551F6
CAGE
127U8
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
  • Veteran Owned Business
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
SAM.gov registration date
Physical address
747 SW 2nd Ave #247, Gainesville, FL 32601, USA
Website
serodopatherapeutics.com
Founded
2017
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Serodopa Therapeutics Inc.'s latest federal award, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
NX90: a treatment for overdose caused by high potency opioids - project summary there has been a dramatic rise in… Grant · R44DA061722 National Institute on Drug Abuse $2,946,808

Quick answers

What is Serodopa Therapeutics Inc.'s UEI?

Serodopa Therapeutics Inc.'s Unique Entity ID (UEI) in SAM.gov is V53SJEC551F6.

What is Serodopa Therapeutics Inc.'s CAGE code?

Serodopa Therapeutics Inc.'s CAGE code is 127U8.

What is Serodopa Therapeutics Inc.'s primary NAICS code?

Serodopa Therapeutics Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Where is Serodopa Therapeutics Inc. located?

Serodopa Therapeutics Inc.'s physical address in SAM.gov is 747 SW 2nd Ave #247, Gainesville, FL 32601, USA.

Is Serodopa Therapeutics Inc. registered in SAM.gov?

Yes. Serodopa Therapeutics Inc.'s SAM.gov registration is active through March 3, 2027.

What is Serodopa Therapeutics Inc.'s most recent federal award?

Serodopa Therapeutics Inc.'s most recent federal grant award is NX90: a treatment for overdose caused by high potency opioids - project summary there has been a dramatic rise in… (R44DA061722), from National Institute on Drug Abuse, on September 30, 2024.

On GovTribe

See Serodopa Therapeutics Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login